Composition containing glutathione and treatment method

A topical composition of nanosized L-glutathione with gamma-cyclodextrin and ascorbic acid addresses the inefficiencies of oral glutathione administration, providing stable and effective transdermal delivery for a range of diseases.

KR103046104B1Active Publication Date: 2026-11-10아우로 파마슈티칼스 인코퍼레이티드
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020227044812
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-22
Filing Date
2021-05-20
Publication Date
2026-11-10
Estimated Expiration
2041-05-20

AI Technical Summary

Technical Problem

Existing methods for administering glutathione are inefficient due to its rapid oxidation and poor absorption through the gastrointestinal tract, limiting its therapeutic effectiveness for various pathological conditions.

Method used

A composition comprising nanosized, non-esterified L-glutathione, gamma-cyclodextrin, and ascorbic acid, with optional additives, is administered topically to bypass gastrointestinal absorption and stabilize glutathione, enhancing its delivery through the skin.

Benefits of technology

The composition allows for effective transdermal delivery of glutathione, increasing its bioavailability and therapeutic efficacy for conditions such as COVID-19, herpes, and other diseases by stabilizing the molecule and avoiding oxidative degradation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112022137354304-PCT00001
    Figure 112022137354304-PCT00001
Patent Text Reader

Abstract

A treatment method is disclosed comprising the step of administering a composition of cyclodextrin and nano-sized L-glutathione to a subject requiring treatment. The composition may be administered topically.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] Related applications

[0002] This application claims priority to U.S. Provisional Application No. 63 / 029,240 filed on May 22, 2020, the contents of which are incorporated herein by reference in their entirety.

[0003] The subject matter disclosed herein relates to the field of pharmaceutical treatment. In particular, the subject matter relates to compositions and treatment methods particularly comprising glutathione. Background Technology

[0004] Glutathione (c-glutamylcysteinylglycine, GSH) is a major thiolized small peptide present in living cells. Due to its reducing and nucleophilic properties, GSH acts as a redox buffer to prevent oxidative damage. Glutathione depletion has been observed in various pathological conditions, including acute respiratory diseases and pulmonary and neurological disorders such as Parkinson's disease. Glutathione is necessary not only for the treatment of alcohol and drug intoxication but also for protection against toxicity induced by cytotoxic chemotherapy and traumatic radiation, as well as for the treatment of AIDS-related cachexia. It is desirable to apply the therapeutic effects of glutathione to the treatment of additional pathological conditions.

[0005] A topical composition is provided herein comprising: reduced and nanosized L-glutathione that is non-esterified, non-acetylated, and non-fatty acid attached; gamma cyclodextrin; ascorbic acid; and one or more compounds selected from the group consisting of dexpanthenol, thiamine, benzalkonium chloride, sodium hyaluronate, and acetyl-L-cysteine; wherein the weight ratio of glutathione to ascorbic acid is between about 7:1 and 15:1. In another embodiment, the weight ratio of glutathione to ascorbic acid is between about 1:1 and 1:15. In another embodiment, the one or more compounds are selected from the group consisting of dexpanthenol, thiamine, benzalkonium chloride, sodium hyaluronate, acetyl-L-cysteine, and potassium sorbate. Specific details for implementing the invention

[0006] In some embodiments of the composition described herein, the weight ratio of glutathione to ascorbic acid is 7:1. In some embodiments, the weight ratio is 10:1. In some embodiments, the weight ratio is 14:1. In some embodiments, the weight ratio is a range of about 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 1:15, 1:14, 1:13, 1:12, 1:11, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, or any ratio between these.

[0007] Some embodiments described herein relate to a method of treating a subject, comprising administering a topical composition to a portion of the skin of the subject, wherein the composition comprises: reduced and nanosized L-glutathione, which is non-esterified, non-cetylated, and non-fatty acid attached; gamma cyclodextrin; and ascorbic acid; wherein the weight ratio of glutathione to ascorbic acid is about 7:1 to 15:1; and wherein the composition is administered between 1 and 10 times per day. In some embodiments, the weight ratio of glutathione to ascorbic acid is between about 1:1 and 1:15.

[0008] In some embodiments, the composition further comprises one or more of dexpanthenol, thiamine, benzalkonium chloride, sodium hyaluronate, and acetyl-L-cysteine. In some embodiments, the composition further comprises one or more of dexpanthenol, thiamine, benzalkonium chloride, sodium hyaluronate, acetyl-L-cysteine, and potassium sorbate. In some embodiments, about 0.15 ml of the composition per dose is administered to the skin. In some embodiments, about 0.5 ml of the composition per dose is administered to the skin. In some embodiments, about 1.25 ml of the composition per dose is administered to the skin. Some embodiments include glycerin, Leuconostoc / radish root fermentation filtrate, Honeysuckle flower extract, Lonicera caprifolium (honeysuckle) extract, It further includes a preservative mixture which is a mixture of American aspen bark extract and gluconolactone.

[0009] In some embodiments, the composition is administered once. In some embodiments, the composition is administered once a day. In some embodiments, the composition is administered twice a day. In some embodiments, the composition is administered every four hours.

[0010] In some embodiments, the administration period is 1 day. In some embodiments, the administration period is 2 weeks. In some embodiments, the administration period is 60 days. In some embodiments, the administration period is 4 months.

[0011] In some embodiments, the composition is about 0.8 cm 2 It is administered to the surface area of ​​the skin. In some embodiments, the composition is about 24 in 2 It is administered to the surface area of ​​the skin. In some embodiments, the composition is about 25 in 2 It is administered to the surface area of ​​the skin. Depending on the embodiment, any surface area falling between the above may be used.

[0012] In some embodiments, the patient is being treated for one or more of influenza, COVID-19, herpes simplex, herpes zoster, postherpetic neuralgia, genital herpes, alcohol detoxification, hypertriglyceridemia, age spots or liver spots, and lupus.

[0013] A treatment method is provided herein comprising the step of administering a composition comprising cyclodextrin and nano-sized L-glutathione to a patient requiring treatment. The composition may optionally include other molecules such as antioxidants.

[0014] In certain embodiments, the cyclodextrin is gamma cyclodextrin. The composition sometimes comprises one or more of L-glutathione and nano-reduced glutathione (RealGSH™). In some embodiments, a natural molecule is present, wherein the natural molecule comprises at least one of a protein, a fragment thereof, and a polypeptide.

[0015] Gamma-cyclodextrin further facilitates the transdermal and transmucosal delivery of the aforementioned molecules, thereby bypassing the gastrointestinal tract and eliminating the need for intravenous administration. Transdermal stabilized glutathione is a new form of glutathione stabilized using encapsulation of a gamma-cyclodextrin ring structure that prevents the oxidation of reduced glutathione by atmospheric oxygen.

[0016] In some embodiments, the natural molecule comprises at least one of a nucleic acid and a fragment thereof. The fragment thereof may comprise at least one of an oligonucleotide, DNA, and RNA.

[0017] Antioxidants

[0018] Antioxidants are molecules capable of inhibiting the oxidation of other molecules. Oxidation is a chemical reaction that transfers electrons from a substance to an oxidizing agent. Oxidation reactions can produce free radicals. In turn, these radicals can initiate a chain reaction. If a chain reaction occurs in a cell, it can cause damage or cell death. Antioxidants terminate these chain reactions and inhibit other oxidation reactions by removing free radical intermediates. Since antioxidants perform this function by oxidizing themselves, they are often reducing agents containing thiols, such as GSH, ascorbic acid, or polyphenols. Thiol groups exist in animal cells at a concentration of approximately 5 mM. Glutathione acts as an electron donor, reducing disulfide bonds formed within cytoplasmic proteins to cysteine. In this process, glutathione is converted into its oxidized form, glutathione disulfide (GSSG).

[0019] Oxidation reactions are critical to life but can also cause damage, and oxidative stress appears to be a significant part of many human diseases. Therefore, plants and animals maintain complex systems of various types of antioxidants, such as GSH, vitamin C, and vitamin E, as well as enzymes like catalase, superoxide dismutase, and various peroxidases. Low levels of antioxidants, or inhibition of antioxidant enzymes, can induce oxidative stress and damage or kill cells.

[0020] In certain embodiments, the antioxidant comprises at least one of alpha-lipoic acid, ascorbic acid, uric acid, beta-carotene, alpha-tocopherol, dimethylethanolamine (DMAE), coenzyme Q10, vitamin E, carnosine, colloidal silver, and enzymes catalase, superoxide dismutase, and peroxidase. The composition may comprise one or more carriers selected from liquids, sprays, aerosols, creams, serums, tablets, capsules, suppositories, lotions, aqueous solutions, powders, pastes, ointments, jellies, waxes, oils, lipids, lipids containing vesicles (cationic or anionic) (e.g., Lipofectin™), DNA conjugates, anhydrous absorbent pastes, oil-in-water and water-in-oil emulsions, emulsions, carbowax (polyethylene glycol of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax.

[0021] The antioxidant is a soluble compound having antioxidant activity and comprising a mixture of two or more of ascorbic acid, ascorbic acid derivatives, L-cysteine, N-acetylcysteine, L-carnitine, acetyl-L-carnitine, riboflavin, and curcuminoids. The antioxidant may be in the range of 0.001 mole to 100 moles per mole of nano-sized L-glutathione, and in a specific embodiment, the antioxidant is 0.01 mole or more and 10 moles or less per mole of nano-sized L-glutathione.

[0022] Antioxidants (e.g. ascorbic acid) are 1000mg / ml, 900mg / ml, 800mg / ml, 700mg / ml, 600mg / ml, 500mg / ml, 450mg / ml, 400mg / ml, 350mg / ml, 300mg / ml, 250mg / ml, 225mg / ml, 200mg / ml, 175mg / ml, 150mg / ml, 100mg / ml, 90mg / ml, 80mg / ml, 70mg / ml, 60mg / ml, 50mg / ml, 40mg / ml, 30mg / ml, 20mg / ml, 10mg / ml, 8mg / ml, 6mg / ml, 5mg / ml, 4mg / ml, 3mg / ml, 2mg / ml, It may be present at a concentration of 1 mg / ml or any amount between the aforementioned concentrations. An antioxidant (e.g., ascorbic acid) may be present between about 350 and 150 mg / ml. A sample composition in which the antioxidant is present at a concentration of 250 mg / ml is shown in Table 1.

[0023] Sample composition. ingredient Concentration (mg / ml) Ascorbic acid 250 Dexpanthenol 25 Cyclodextrin 50 glutathione 10 Preservative mixture* 20 Potassium sorbate 1 sodium hyaluronate 1

[0024] The preservative mixture consists of glycerin, Leuconostoc / radish root fermentation filtrate, Honeysuckle flower extract, Lonicera caprifolium (honeysuckle) extract, It is a mixture of American aspen bark extract and gluconolactone.

[0025] Cyclodextrin

[0026] Cyclodextrin (sometimes called cycloamylose) is a family of compounds composed of sugar molecules (cyclic oligosaccharides) linked together in a ring and is produced from starch through enzymatic conversion. Cyclodextrin is used in the food, pharmaceutical, chemical, agricultural, and environmental engineering industries.

[0027] Cyclodextrin consists of five or more (1,4)-linked α-D-glucopyranose units. Topologically, cyclodextrin forms a torus that is hydrophobic on the inside and hydrophilic on the outside. Conventional cyclodextrins form a cone shape containing many glucose monomers in the range of 6 to 8 units in the ring. Alpha-cyclodextrin is a hexa-sugar ring molecule, beta-cyclodextrin is a heptacid ring molecule, and gamma-cyclodextrin is an octacid ring molecule. Cyclodextrin can be topologically represented as a torus having a larger opening and a smaller opening of the toroid exposed to the solvent secondary and primary hydroxyl groups, respectively. Due to this arrangement, the interior of the toroid is not hydrophobic but is significantly less hydrophilic than the aqueous environment and can therefore accommodate other hydrophobic molecules. In contrast, the exterior is sufficiently hydrophilic to impart water solubility to the cyclodextrin (or its complex).

[0028] This allows cyclodextrin to act as a host molecule that forms inclusion complexes with hydrophobic guest molecules. Cyclodextrin is known to influence the transdermal absorption of therapeutic agents by increasing drug availability at the absorption site through its solubilizing action and by improving transdermal penetration through interactions with free lipids present in the stratum corneum.

[0029] The formation of inclusion compounds significantly alters the physical and chemical properties of guest molecules, primarily in terms of water solubility. Thus, inclusion compounds of cyclodextrins containing hydrophobic molecules can penetrate body tissues and be used to release biologically active compounds under specific conditions. The controlled degradation mechanism of these complexes sometimes results in the cleavage of hydrogen or ionic bonds between host and guest molecules based on changes in the pH of the solution. Alternative means for complex destruction may involve heating or the action of enzymes capable of cleaving the α-1,4 linkages between glucose monomers.

[0030] In a cyclodextrin inclusion, one or more guest molecules interact with the cavity of the cyclodextrin molecule to form a stable association. Molecules or functional groups of molecules that are less hydrophilic than water may be incorporated into the cyclodextrin cavity in the presence of water. “Guest molecules” may be at least partially fitted into the cyclodextrin cavity. The cavity size and possible chemical modifications determine the affinity of the cyclodextrin for various molecules. For some low molecular weight molecules, more than one guest molecule may be fitted into the cavity. Conversely, some high molecular weight molecules may bind to more than one cyclodextrin molecule. Therefore, a 1:1 molar ratio is not always achieved. Gamma-cyclodextrin as provided herein exhibits compatibility with glutathione and protects the glutathione molecule sufficiently to usefully extend the glutathione half-life in the bloodstream.

[0031] In the solid state, guest molecules are molecularly dispersed within the cyclodextrin matrix, even when they are present with gaseous guest molecules. Therefore, guest molecules are effectively protected from all types of reactions except for the hydroxyl groups of the cyclodextrin. In aqueous solution, the concentration of sparingly soluble guest molecules in the dissolved state increases significantly. The reactivity of guest molecules decreases in most cases.

[0032] Cyclodextrin can form inclusion complexes with a wide range of hydrophobic molecules, and larger gamma-cyclodextrin accommodates bulkier compounds. As provided herein, cyclodextrin and gamma-cyclodextrin can form compounds, in particular, with peptides, polypeptides, proteins, amino acids, nucleic acids, polynucleotides, DNA, and RNA antioxidants such as ascorbic acid, carnosine, alpha-lipoic acid, DMAE, and coenzyme Q10, and other molecules such as colloidal silver can enhance the protective function of the complex and perform various other functions.

[0033] Cyclodextrin conjugation of drugs can increase drug stability, sustain release, and minimize photodegradation of the conjugated drug. Cyclodextrin conjugation is useful for improving the chemical, physical, and thermal stability of drugs. When an active molecule is exposed to oxygen, water, radiation, or heat, a chemical reaction is required for it to degrade. When a molecule is trapped within a cyclodextrin cavity, reactants diffuse into the cavity, making it difficult for them to react with the protected guest.

[0034] Stabilized cyclodextrin-glutathione compounds appear in the form of a gel applied topically. The cyclodextrin ring structure is broken down by enzymes naturally occurring in the skin, and the reduced glutathione is absorbed transdermally and enters the bloodstream.

[0035] glutathione

[0036] Glutathione (GSH) as provided herein is natural, non-esterified, non-cetylated, and non-fatty acid attached, promoting high bioavailability. Glutathione is a tripeptide containing a specific peptide bond between the amine group of cysteine ​​and the carboxyl group of the glutamate side chain. It is an antioxidant that prevents damage to various cellular components caused by reactive oxygen species, such as free radicals and peroxides. Glutathione is the most abundant low-molecular-weight thiol tripeptide synthesized in cells and helps maintain other antioxidants (e.g., Vitamin C) in their active reduced forms. Due to the unstable nature of glutathione caused by its cysteine ​​moiety, its clinical use in medicine has been limited. Consequently, when glutathione is administered intravenously, most of it is oxidized to GSSG in the IV bag during storage, transport, or infusion. Although spray forms have also been used, odor and taste reduce patient compliance, and it is not intuitive to suggest that aerosolizing highly reactive compounds in the presence of atmospheric oxygen is an effective strategy.

[0037] In vivo, glutathione is found almost exclusively in its reduced form because glutathione reductase, the enzyme that reverts it from its oxidized state, is structurally active and induced by oxidative stress. In fact, the ratio of reduced to oxidized glutathione within cells is often used as a measure of cytotoxicity. Glutathione prevents cell damage by neutralizing harmful molecules generated during energy production. Glutathione also plays a role in processing drugs and cancer-causing compounds (carcinogens) and in building DNA, proteins, and other important cellular components.

[0038] Glutathione is known as a substrate in both conjugation and reduction reactions catalyzed by glutathione S-transferase in the cytosol, microsomes, and mitochondria. However, it may also participate in non-enzymatic conjugation with certain chemicals. Glutathione participates in leukotriene synthesis and is a cofactor for the enzyme glutathione peroxidase. It is also important as a hydrophilic molecule that is added to lipophilic toxins and waste products in the liver during in vivo changes before becoming part of bile. Glutathione also assists in the detoxification of methylglyoxal, a toxin produced as a metabolic byproduct.

[0039] Low glutathione levels are strongly associated with wasting and negative nitrogen balance, as seen in cancer, AIDS, sepsis, trauma, burns, and even excessive exercise training. Glutathione supplementation can disrupt this process, improving survival rates, for example, in the case of AIDS. Schizophrenia and bipolar disorder are associated with low glutathione levels. Cumulative data suggest that oxidative stress may be a fundamental factor in the pathophysiology of bipolar disorder (BD), major depressive disorder (MDD), and schizophrenia (SCZ). Glutathione is the brain's primary free radical scavenger. Reduced glutathione levels increase cellular vulnerability to oxidative stress and are characterized by the accumulation of reactive oxygen species. Glutathione supplementation using N-acetylcysteine ​​has been shown to reduce the symptoms of these disorders.

[0040] Glutathione is an antidote for acetaminophen overdose, which becomes toxic when glutathione is depleted due to an overdose of N-acetyl-p-benzoquinoneimine (NAPQI), a reactive cytochrome P450 metabolite formed by paracetamol (known as acetaminophen in the United States). Glutathione conjugates to NAPQI to aid in its detoxification. With this ability, it protects the thiol groups of cellular proteins, which would otherwise be covalently modified; when all glutathione is consumed, NAPQI begins to react with cellular proteins, killing the cell in the process.

[0041] Preliminary results on isolated cells indicate that glutathione can reduce cancer development by altering levels of reactive oxygen species. Further evidence suggests that adequate levels of glutathione help regulate levels of tumor necrosis factor (TNF), a group of cytokines capable of inducing apoptosis. However, once cancer has developed, elevated levels of GSH in tumor cells confer resistance to many chemotherapy drugs and thus protect cancer cells in bone marrow, breast, colon, laryngeal, and lung cancers.

[0042] At synapses, excessive glutamate, which can be released under conditions such as traumatic brain injury, can interfere with the absorption of cysteine, an essential component of glutathione. Without the protection against oxidative damage provided by glutathione, cells may be damaged or die.

[0043] It is difficult to increase glutathione levels by directly supplementing with glutathione. Studies show that orally ingested glutathione is broken down by digestive enzymes and is not well absorbed through the gastrointestinal tract. Additionally, natural GSH can oxidize very rapidly when exposed to air. There have been some attempts to stabilize glutathione by acetylating or esterifying the glutathione thiol group.

[0044] A complex of nanosized L-glutathione and gamma-cyclodextrin protects glutathione from degradation and oxidation without the need to alter natural glutathione molecules.

[0045] nano-sized glutathione Cyclodextrin complex

[0046] Nano-sizing of pH-stabilized glutathione cyclodextrin complexes can promote rapid absorption into the bloodstream. In some embodiments, sodium hydroxide, hydrochloric acid, or other acids are added to the stabilized glutathione and gamma cyclodextrin to adjust the pH of the solution. In various embodiments, the pH is adjusted to a pH between 4.00 and 7.8. In certain embodiments, the adjusted pH is between 5.00 and 7.2. The solution may be nano-sized using ultrasound known in the art in the range of about 100 watts. The ultrasound is sometimes applied for a duration of 1 minute to 10 minutes. In certain embodiments, the ultrasound is applied for a duration of 3 minutes to 6 minutes.

[0047] The size of the generated nanoparticles may be in the range of 2 nanometers to 200 nanometers. In certain embodiments, the nanoparticles have sizes in the range of 2 to 20 nanometers, 20 to 40 nanometers, 40 to 60 nanometers, 60 to 80 nanometers, 80 to 100 nanometers, 100 to 120 nanometers, 120 to 140 nanometers, 140 to 160 nanometers, 160 to 180 nanometers, and 180 to 200 nanometers. In some embodiments, the nanoparticles may have mixed sizes.

[0048] Therapeutic administration and formulation

[0049] The composition described herein may be an effective outpatient treatment for COVID-19 disease. Early treatment can prevent cytokine storm syndrome that may be associated with COVID-19, reduce the time to resolution of all symptoms, and restore the patient's sense of well-being.

[0050] The compositions provided herein may be formulated into liquids, creams, serums, solids, lotions, oils, emulsions, sprays, aerosols, dissolving strips, boluses, suppositories, tablets, capsules, or other formulations using compounding and other methods known in the art. In certain embodiments, a guest molecule such as gamma-cyclodextrin and GSH are combined in an aqueous solution containing ascorbic acid and benzalkonium chloride, mixed at a pH of about 3.0 to about 7.0, and then capped under vacuum. In some embodiments, the pH is about 5.5. In certain embodiments, the pH is about 3.0 to about 4.0, about 4.0 to about 5.0, about 5.0 to about 6.0, or about 6.0 to about 7.0.

[0051] The percentage of cyclodextrin may be 1% to 50%. The percentage of cyclodextrin may sometimes be 1% to 5%, 5% to 10%, 10% to 15%, 15% to 20%, 20% to 25%, 25% to 30%, 30% to 35%, 35% to 40%, 40% to 45%, or 45% to 50%. The percentage of glutathione or other guest molecules may be 0.1% to 80%. In a specific embodiment, the percentage of glutathione or other guest molecules is 0.1% to 1%, 1% to 5%, 5% to 10%, 10% to 15%, 15% to 20%, 20% to 30%, 30% to 40%, 40% to 50%, 50% to 60%, 60% to 70%, 70% to 80%, 80% to 85%, 85% to 90%, or 90% to 95% (or any percentage between the foregoing).

[0052] In some embodiments, cyclodextrin is present at a concentration of approximately 69 mg / ml, 120 mg / ml, 155 mg / ml, or 250 mg / ml. In various embodiments, glutathione is present at a concentration of approximately 200 mg / ml, 350 mg / ml, or 550 mg / ml. The molar ratio of glutathione to cyclodextrin is sometimes 26:1. The molar ratio of GSH to cyclodextrin may be 1:15 or less to 30:1 or more. As a non-limiting example, the molar ratio of glutathione or other guest molecule to cyclodextrin may be 1:15, 1:14, 1:13, 1:12, 1:11, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2 and 1:1, or some of the aforementioned ratios. In certain embodiments, the molar ratio of GSH or other guest molecule to cyclodextrin is 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, and It is 30:1, or a part of the ratios described above. In certain embodiments, the concentration of glutathione is 950 mg / ml. In various embodiments, the concentration of cyclodextrin is 150 mg / ml. The cyclodextrin as provided above is sometimes gamma-cyclodextrin. In some embodiments, the combined concentration percentage is 95% GSH in 15% gamma-cyclodextrin.

[0053] Various natural molecules can be combined with cyclodextrin in a similar manner to form inclusion complexes. In certain embodiments, antioxidants and other molecules may be added, including but not limited to ascorbic acid, alpha-lipoic acid, uric acid, alpha-tocopherol, beta-carotene, or other antioxidant molecules.

[0054] Specifically, the compositions of certain embodiments disclosed herein contain nanosized L-glutathione in a stabilizing solution that may contain an antioxidant. The antioxidant may be any soluble compound having antioxidant activity, which may be a mixture of two or more of ascorbic acid, ascorbic acid derivatives, L-cysteine, N-acetylcysteine, L-carnitine, acetyl-L-carnitine, riboflavin, and curcuminoids. In some embodiments, the antioxidant may be 0.001 moles or more and 100 moles or less per mole of reduced L-glutathione, and 0.01 moles or more and 10 moles or less of reduced L-glutathione.

[0055] The composition and method may be administered under a physician's prescription or as a general medicine, depending on the natural molecules and other components comprising the composition and the condition to be treated. The route of administration is according to known methods, including but not limited to oral, sublingual, transdermal, cutaneous, subcutaneous, mucosal, transmucosa, inhalation, intralesional, buccal, or by the sustained-release systems described below. In some embodiments, the composition as provided herein is administered via a small strip or other form of material that can dissolve in the patient's mouth. This enables the convenience of solid-form therapy while maintaining the benefits of sublingual or mucosal delivery. Enzymes in the human mouth can break down carbohydrates but cannot break down peptides, proteins, or various types of organic molecules. Therefore, the composition can be delivered directly into the bloodstream without the need for intravenous delivery, without exposure to digestive enzymes or crossing the intestinal barrier.

[0056] The therapeutic compositions disclosed herein may be administered via the skin, mucous membranes, nose, eyes, or lungs in formulations comprising liquids, creams, serums, lotions, oils, emulsions, gels, pastes, powders, liquid or powder aerosols (freeze-dried). The compositions may be administered parenterally or subcutaneously as needed. The compositions may be administered systemically and may be sterile, pyrogen-free, and parenterally acceptable solutions with sufficient consideration for pH, isotonicity, and stability. These conditions are known to those skilled in the art. Briefly, administration formulations of the compounds described herein are prepared for storage or administration by mixing compounds of a desired degree of purity with physiologically acceptable carriers, excipients, or stabilizers, such as cyclodextrin and gamma-cyclodextrin. These materials are non-toxic to the recipient at the doses and concentrations used and buffers such as TRIS HCl, phosphates, citrates, acetates, and other organic acid salts; Antioxidants such as ascorbic acid, carnosme, and alpha-lipoic acid; proteins such as peptides such as polyarginine, serum albumin, gelatin, or immunoglobulin; hydrophilic polymers such as polyvinylpyrrolidinone; amino acids such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrin; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterionic agents such as sodium and / or nonionic surfactants such as TWEEN, PLURONICS, or polyethylene glycol may be included.

[0057] Suitable examples of sustained-release formulations include a semipermeable matrix of a solid hydrophobic polymer containing the provided composition, said matrix being in the form of a shaped article, film, or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers, such as poly-D-(-)-3-hydroxybutyric acid.

[0058] Polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable the release of molecules for more than 100 days, whereas certain hydrogels release proteins for a shorter period. If encapsulated proteins remain in the body for a long time, exposure to moisture at 37°C can cause denaturation or aggregation, leading to a loss of biological activity and changes in immunogenicity. Reasonable strategies for protein stabilization can be devised based on the underlying mechanisms. For example, if the aggregation mechanism is found to be the formation of intermolecular S-S bonds via disulfide exchange, stabilization can be achieved by modifying sulfhydryl residues, freeze-drying in acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

[0059] For a given patient, the dosage of the composition of the present invention will be determined by a therapist or physician, taking into account the natural molecules comprising the composition, the severity and type of the disease, body weight, gender, diet, time and route of administration, other drugs, and various factors known to alter the action of the drug, including other relevant clinical factors. The therapeutically effective dosage may be determined by in vitro or in vivo methods.

[0060] The effective dose of the composition of the present invention to be used therapeutically will vary, for example, depending on the therapeutic purpose, the route of administration, and the patient's condition. Accordingly, the therapist may titrate the dose and modify the route of administration as necessary to obtain the optimal therapeutic effect. The daily dose may range from about 0.001 mg / kg to more than 100 mg / kg depending on the factors mentioned above. In some embodiments, the dose is 50, 100, or 200 mg of GSH administered as a topical gel. In some embodiments, this dose is administered twice daily, once in the morning and once in the afternoon. The clinician may administer the therapeutic composition as provided herein until the dose that achieves the desired effect is reached. The progress of this therapy may be monitored by conventional analytical methods or as described herein.

[0061] In some embodiments, approximately 0.15 ml, 0.5 ml, or 1.25 ml of the composition is applied topically. In some embodiments, the composition is approximately 0.5 cm 2 Up to about 25 in 2 (For example, 0.8cm 2 , 24in 2 , or 25in 2 It is applied to a portion of the skin of ). In some embodiments, the composition is applied once a day, twice a day, or every four hours. In some embodiments, the composition is applied for a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 20, 30, 40, 50, or 60 days. In some embodiments, the composition is applied for a period of approximately 3, 4, 5, or 6 months, or approximately 1 year.

[0062] The therapeutic substance according to the composition and method of the present invention may be administered with suitable carriers, excipients, and other agents incorporated into formulations to provide improved transport, delivery, tolerance, etc. These formulations include powders, pastes, ointments, jellies, waxes, oils, lipids, (cationic or anionic) lipids containing vesicles (such as Lipopectin™), DNA conjugates, anhydrous absorbent pastes, oil-in-water and water-in-oil emulsions, emulsion carbowaxes (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowaxes. Any of the aforementioned mixtures may be suitable for the treatment and therapy according to the composition, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically suitable and tolerable to the route of administration as known in the art.

[0063] Embodiments may be carried out in other specific forms. The described embodiments are to be regarded as illustrative in all respects and not limiting. Accordingly, the scope of the invention is defined by the appended claims rather than by the foregoing description. Any modifications occurring within the meaning and scope of the claims are included therein.

[0064] In some embodiments, a therapeutic method is also provided herein, comprising the step of administering a composition of cyclodextrin, nanosized glutathione, and an antioxidant to a patient to treat a specific pathological condition. The patient may be an animal selected from the group consisting of mammals, birds, reptiles, amphibians, and fish. Mammals are sometimes humans.

[0065] In a specific embodiment, the condition to be treated includes one or more of alcohol or drug intoxication, intoxication, alcohol “hangover,” toxicity induced by cytotoxic chemotherapy, radiation trauma, AIDS-related cachexia, HIV AIDS, shingles, frostbite, heavy metal poisoning, laser burns, sunburns, traumatic burns, thermal burns, burns including chemical burns, acne, pressure ulcers, autism, scar tissue, Parkinson’s disease, hepatitis B, hepatitis C, upper respiratory viral infection (common cold), cystic fibrosis, insect bites (mosquito, spider, etc.), limb pain, neuropathy, reflex sympathetic dystrophy (RSD), rheumatoid arthritis, multiple sclerosis, osteoarthritis, psoriasis, psoriatic arthritis, jet lag indications, renal disease (CRF, CKD), akathisia, and tardive dyskinesia.

[0066] In various embodiments, the conditions to be treated include obesity, immunosuppression, inflammation, angina pectoris, heart disease, and cardiac reperfusion injury; acute respiratory diseases, emphysema, pulmonary fibrosis and related muscle wasting, pulmonary and neurological diseases such as asthma and migraine; Parkinson's disease, herpes zoster, HSV, hepatitis B and C, and influenza, fibromyalgia; osteoporosis / osteomalacia, cancer including but not limited to brain, head and neck, thyroid, lung, esophagus, stomach, intestine, liver, pancreas, kidney, uterus, ovary, prostate, leukemia (acute and chronic), lymphoma, and multiple myeloma; systemic sclerosis (scleroderma) syndrome, sepsis, trauma, wrinkles, sagging skin, acne, atopic dermatitis and eczema, excessive exercise training and muscle fatigue; schizophrenia, bipolar disorder, major depressive disorder, dementia, autism, attention deficit hyperactivity disorder (ADHD); acetaminophen overdose, low energy, drug toxicity; It includes one or more of the following: cataracts, glaucoma, macular degeneration, macular dystrophy, diabetic retinopathy, vision loss, diabetic retinopathy, and contrast sensitivity; biomolecular imbalances caused by traumatic head injury or other causes; and infertility in men and women.

[0067] In some embodiments, the conditions to be treated include one or more of COVID-19, herpes simplex, postherpetic neuralgia, genital herpes, hypertriglyceridemia, liver spots or liver spots, and lupus.

[0068] An embodiment of a kit for topical application is further provided herein, comprising a complex of cyclodextrin and nano-sized L-glutathione, a container for dispensing the composition, a device for topical application of the composition, and one or more instructions for use.

[0069] Throughout this specification, references to “some embodiments,” “specific embodiments,” “various embodiments,” or similar language mean that the specific features, structures, or characteristics described in relation to such embodiments are included in at least one embodiment. Accordingly, throughout this specification, the phrases “in some embodiments,” “in specific embodiments,” “in various embodiments,” and the appearance of similar language may all refer to the same embodiment, but are not necessarily so, and mean “one or more, but not all” unless otherwise explicitly specified. “Included,” “included,” “including,” “having,” and variations thereof mean “including but not limited thereto” unless otherwise explicitly specified. An enumerated list of items does not mean that some or all items are mutually exclusive and / or mutually inclusive unless otherwise explicitly specified. The terms “a,” “an,” and “the” (singular) mean “one or more” unless otherwise explicitly specified.

[0070] Additionally, the described features, structures, or properties of the embodiments may be combined in any suitable manner. However, those skilled in the art will recognize that the embodiments may be implemented without one or more specific details or with other methods, components, materials, etc. Rather, language referring to features and advantages is understood to mean that a specific feature, advantage, or property is included in at least one embodiment. Accordingly, discussions of features and advantages and similar language throughout this specification may refer to the same embodiment, but not necessarily. In other cases, well-known protocols, reagents, materials, or operations are not described in detail to avoid obscuring aspects of the embodiments.

[0071] Examples

[0072] Examples 1: Using a glutathione composition COVID Randomized controlled trials for COVID-19 virus treatment

[0073] A sample size of 186 adults is selected for the study. Inclusion criteria for subject selection are as follows: SARS-CoV-2 laboratory (RT-PCR) positivity, age over 60, willingness to participate in a randomized controlled trial, SaO2 / SPO2 ratio greater than 95%, and AST / ALT less than 5 times normal. Exclusion criteria for subject selection are as follows: patients positive for COVID-19 but asymptomatic, pulmonary pneumonia secondary to bacterial infection, pregnancy, severe or critical illness, severe or renal failure, and a GFR less than 50. Selected subjects are those exhibiting at least symptoms of fever, shortness of breath, or a dry cough. Subjects may have additional symptoms such as body aches and pains or fatigue.

[0074] Half of the subjects (control group) are provided with a placebo, and the other half (experimental group) are provided with the following topical glutathione composition:

[0075] Glutathione 350mg / ml;

[0076] Ascorbic acid 50 mg / ml;

[0077] Dexpanthenol 2 mg / ml; and

[0078] Cyclodextrin 155 mg / ml

[0079] Each subject will apply 0.5 ml of the composition (or placebo) every 4 hours for 5 days or until symptoms subside. After that, the subject will apply 0.5 ml twice a day for 14 days.

[0080] All subjects are monitored for clinical recovery time, defined as the resolution of fever and cough that persist for at least 72 hours. Fever is resolved when the subject's body temperature reaches 36.6°C at the surface, 37.2°C in the armpits and mouth, and 37.8°C in the rectum and eardrum. Cough is resolved when the subject reports having a slight cough or no cough. Temperature and cough are checked three times daily.

[0081] Only 7% of subjects in the control group develop serious diseases, while approximately 13.8% are estimated to receive no treatment. Additionally, only 3% of subjects in the control group require mechanical ventilation, while 6.1% are estimated to receive no treatment.

[0082] Examples 2: Using a glutathione composition COVID Randomized controlled trials for COVID-19 virus treatment

[0083] This study included 10 individuals. After explaining the risks and benefits via a telemedicine visit, they were provided with Glutaryl™ for self-administration. Data were collected during the initial telemedicine visit to record symptoms, age, gender, and chronic diseases. Symptom documentation followed World Health Organization (WHO) standards. Prior to July 2020, individuals were not asked about nausea as it was not yet a symptom recognized by the WHO. The administration protocol was to administer four sprays five times a day for five days, followed by four sprays twice a day for two weeks. It was sprayed onto the abdomen and absorbed into the systemic circulation. Clinical response was reviewed via telemedicine visits on days 3, 7, and 10 following the administration of Glutarlyl™ spray.

[0084] Glutarlyl™ spray contains 200 mg / ml of glutathione, 20 mg / ml of ascorbic acid, and 69 mg / ml of cyclodextrin.

[0085] result

[0086] Table 2 summarizes the responses of 10 individuals. Outcome measures were the onset of the disease and the number of days until symptom resolution across all study items. In all cases, all symptoms resolved and a feeling of health was restored within 2 to 8 days of using Glutaryl™. No hospitalization was required.

[0087] Cases 2, 4, 5, 7, and 8 recovered within 3 days with early treatment. In the case of Cases 1, 3, 6, 9, and 10, a total of 10 to 12 days elapsed from the onset of symptoms to recovery, which likely reflected the effects of chronic disease, advanced age, and / or delayed treatment.

[0088]

[0089] HTN = Hypertension, DM = Diabetes mellitus, n / a = Not asked

Claims

Claim 1 A local composition comprising: reduced and nanosized L-glutathione that is non-esterified, non-cetylated, and non-fatty acid attached; gamma cyclodextrin; ascorbic acid; and one or more compounds selected from the group consisting of dexpanthenol, thiamine, and sodium hyaluronate; wherein the weight ratio of glutathione to ascorbic acid is between 7:1 and 15:

1. Claim 2 A composition according to claim 1, characterized in that the weight ratio is 7:

1. Claim 3 A composition according to claim 1, characterized in that the weight ratio is 10:

1. Claim 4 A composition according to claim 1, characterized in that the weight ratio is 14:

1. Claim 5 A local composition comprising: reduced and nanosized L-glutathione that is non-esterified, non-cetylated, and non-fatty acid attached; gamma cyclodextrin; ascorbic acid; and one or more compounds selected from the group consisting of dexpanthenol, thiamine, sodium hyaluronate, and potassium sorbate; wherein the weight ratio of glutathione to ascorbic acid is between 1:1 and 1:

15. Claim 6 A composition according to claim 5, characterized in that the weight ratio is 1:

10. Claim 7 A composition according to claim 5, characterized in that the weight ratio is 1:

5. Claim 8 A composition according to claim 5, characterized in that the weight ratio is 1:

2. Claim 9 A composition for use in a method for treating COVID-19, in any one of claims 1 to 8. Claim 10 A composition according to claim 9, characterized in that the composition is administered between 1 and 10 times per day. Claim 11 A composition according to claim 9, characterized in that 0.15 ml, 0.5 ml, or 1.25 ml of the composition per volume is administered to the skin. Claim 12 In claim 9, the composition is characterized by being administered once, once a day, or twice a day. Claim 13 In claim 9, the composition is characterized by being administered every 4 hours. Claim 14 A composition according to claim 9, characterized in that the administration period is 1 day, 2 weeks, or 60 days, or 4 months. Claim 15 In claim 9, the above composition is 0.8 cm 2 , 24in 2 , or 25in 2 A composition characterized by being administered to the surface area of ​​the skin. Claim 16 delete Claim 17 delete Claim 18 delete Claim 19 delete Claim 20 delete Claim 21 delete Claim 22 delete Claim 23 delete Claim 24 delete Claim 25 delete Claim 26 delete Claim 27 delete Claim 28 delete Claim 29 delete Claim 30 delete Claim 31 delete Claim 32 delete Claim 33 delete Claim 34 delete Claim 35 delete Claim 36 delete Claim 37 delete Claim 38 delete Claim 39 delete Claim 40 delete Claim 41 delete

Citation Information

Patent Citations

  • Reduced glutathione percutaneous absorption preparation and preparation method thereof

    CN102100904A

  • Method for stabilization and delivery of therapeutic molecules

    US20170095561A1